What is HC Wainwright’s Estimate for COCP Q3 Earnings?

Cocrystal Pharma, Inc. (NASDAQ:COCP) – Analysts at HC Wainwright issued their Q3 2026 EPS estimates for Cocrystal Pharma in a research note issued to investors on Friday, October 9th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of ($0.22) per share for the quarter. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($0.69) per share. HC Wainwright also issued estimates for Cocrystal Pharma’s FY2026 earnings at ($0.76) EPS and FY2027 earnings at ($0.37) EPS.

Separately, Weiss Ratings downgraded shares of Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold”.

Cocrystal Pharma Trading Down 3.7%

COCP stock opened at $1.04 on Tuesday. The firm has a market cap of $20.03 million, a PE ratio of -1.37 and a beta of 1.48. Cocrystal Pharma has a 1 year low of $0.76 and a 1 year high of $2.03. The company has a fifty day simple moving average of $1.13 and a 200 day simple moving average of $1.14.

Cocrystal Pharma (NASDAQ:COCP) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.06). The firm had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.10 million.

About Cocrystal Pharma

Cocrystal Pharma, Inc is a clinical-stage biotechnology company focused on discovering and developing antiviral therapies. The company uses a structure-based drug discovery platform to identify small-molecule compounds designed to interfere with essential viral replication proteins.

Its research programs have targeted a range of viral diseases, including influenza A, norovirus and coronaviruses. Cocrystal’s development activities have included orally administered antiviral candidates intended for the treatment or prevention of viral infections, with programs advancing through a combination of preclinical research and clinical development.

Founded in 2007 and formerly known as BioZone Pharmaceuticals, the company adopted the Cocrystal Pharma name after combining with Cocrystal Discovery in 2015.